James I Geller1, Nicholas G Cost2, Yueh-Yun Chi3, Brett Tornwall3, Mariana Cajaiba4, Elizabeth J Perlman5, Yeonil Kim6, Elizabeth A Mullen7, Richard D Glick8, Geetika Khanna9, Najat C Daw10, Peter Ehrlich11, Conrad V Fernandez12, Jeffrey S Dome13. 1. Division of Pediatric Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio. 2. Division of Urology, Department of Surgery, University of Colorado School of Medicine, the Children's Hospital Colorado, Aurora, Colorado. 3. Department of Biostatistics, Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, Florida. 4. Department of Pathology, Anne and Robert H. Lurie Children's Hospital, University of Michigan School of Medicine, Ann Arbor, Michigan. 5. Department of Pathology, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 6. Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck & Company Inc, Rahway, New Jersey. 7. Department of Pediatric Oncology, Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts. 8. Division of Pediatric Surgery, Steven and Alexandra Cohen Medical Center of New York, New York, New York. 9. Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri. 10. Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 11. Section of Pediatric Surgery, Department of Surgery, C.S. Mott Children's Hospital, University of Michigan School of Medicine, Ann Arbor, Michigan. 12. Division of Pediatric Oncology, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada. 13. Division of Pediatric Oncology, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC.
Abstract
BACKGROUND: To the authors' knowledge, AREN0321 is the first prospective clinical study of pediatric and adolescent renal cell carcinoma (RCC). Goals of the study included establishing epidemiological, treatment, and outcome data and confirming that patients with completely resected pediatric RCC, including lymph node-positive disease (N1), have a favorable prognosis without adjuvant therapy. METHODS: From 2006 to 2012, patients aged <30 years with centrally reviewed pathology of RCC were enrolled prospectively. RESULTS: A total of 68 patients were enrolled (39 of whom were male; median age of 13 years [range, 0.17-22.1 years]). Stage was classified according to the American Joint Committee on Cancer TNM stage seventh edition as stage I in 26 patients, stage II in 7 patients, stage III in 26 patients, and stage IV in 8 patients, and was not available in 1 patient. Sixty patients underwent resection of all known sites of disease, including 2 patients with stage IV disease. Surgery included radical nephrectomy (53 patients [81.5%]), partial nephrectomy (12 patients [18.5%]), and unknown (3 patients [4.4%]). Histology was TFE-associated RCC (translocation-type RCC; tRCC) in 40 patients, RCC not otherwise specified and/or other in 13 patients, papillary RCC in 9 patients, and renal medullary carcinoma (RMC) in 6 patients. Lymph node status was N0 in 21 patients, N1 in 21 patients (tRCC in 15 patients, RMC in 3 patients, papillary RCC in 2 patients, and not otherwise specified and/or other in 1 patient), and Nx in 26 patients. The 4-year event-free survival and overall survival rates were 80.2% (95% CI, 69.6%-90.9%) and 84.8% (95% CI, 75.2%-94.5%), respectively, overall and 87.5% (95% CI, 68.3%-100%) and 87.1% (95% CI, 67.6%-100%), respectively, for the 16 patients with N1M0 disease. Among patients presenting with metastases, 2 of 8 patients (2 of 5 patients with RMC) were alive (1 with disease) at the time of last follow-up, including 1 patient who was lost to follow-up (succinate dehydrogenase deficiency). The predominant RCC subtypes associated with mortality were tRCC and RMC. CONCLUSIONS: Favorable short-term outcomes can be achieved without adjuvant therapy in children and adolescents with completely resected RCC, independent of lymph node status. A prospective study of patients with tRCC and RMC with M1 or recurrent disease is needed to optimize treatment.
BACKGROUND: To the authors' knowledge, AREN0321 is the first prospective clinical study of pediatric and adolescent renal cell carcinoma (RCC). Goals of the study included establishing epidemiological, treatment, and outcome data and confirming that patients with completely resected pediatric RCC, including lymph node-positive disease (N1), have a favorable prognosis without adjuvant therapy. METHODS: From 2006 to 2012, patients aged <30 years with centrally reviewed pathology of RCC were enrolled prospectively. RESULTS: A total of 68 patients were enrolled (39 of whom were male; median age of 13 years [range, 0.17-22.1 years]). Stage was classified according to the American Joint Committee on Cancer TNM stage seventh edition as stage I in 26 patients, stage II in 7 patients, stage III in 26 patients, and stage IV in 8 patients, and was not available in 1 patient. Sixty patients underwent resection of all known sites of disease, including 2 patients with stage IV disease. Surgery included radical nephrectomy (53 patients [81.5%]), partial nephrectomy (12 patients [18.5%]), and unknown (3 patients [4.4%]). Histology was TFE-associated RCC (translocation-type RCC; tRCC) in 40 patients, RCC not otherwise specified and/or other in 13 patients, papillary RCC in 9 patients, and renal medullary carcinoma (RMC) in 6 patients. Lymph node status was N0 in 21 patients, N1 in 21 patients (tRCC in 15 patients, RMC in 3 patients, papillary RCC in 2 patients, and not otherwise specified and/or other in 1 patient), and Nx in 26 patients. The 4-year event-free survival and overall survival rates were 80.2% (95% CI, 69.6%-90.9%) and 84.8% (95% CI, 75.2%-94.5%), respectively, overall and 87.5% (95% CI, 68.3%-100%) and 87.1% (95% CI, 67.6%-100%), respectively, for the 16 patients with N1M0 disease. Among patients presenting with metastases, 2 of 8 patients (2 of 5 patients with RMC) were alive (1 with disease) at the time of last follow-up, including 1 patient who was lost to follow-up (succinate dehydrogenase deficiency). The predominant RCC subtypes associated with mortality were tRCC and RMC. CONCLUSIONS: Favorable short-term outcomes can be achieved without adjuvant therapy in children and adolescents with completely resected RCC, independent of lymph node status. A prospective study of patients with tRCC and RMC with M1 or recurrent disease is needed to optimize treatment.
Authors: Maria Debora de Pasquale; Aurora Castellano; Luigi de Sio; Clementina de Laurentis; Angela Mastronuzzi; Annalisa Serra; Raffaele Cozza; Alessandro Jenkner; Maria Antonietta de Ioris Journal: Anticancer Res Date: 2011-11 Impact factor: 2.480
Authors: Mariana M Cajaiba; Lisa M Dyer; James I Geller; Lawrence J Jennings; David George; Dawn Kirschmann; Stephen M Rohan; Nicholas G Cost; Geetika Khanna; Elizabeth A Mullen; Jeffrey S Dome; Conrad V Fernandez; Elizabeth J Perlman Journal: Cancer Date: 2018-06-15 Impact factor: 6.860
Authors: Allan J Pantuck; Amnon Zisman; Frederich Dorey; Debby H Chao; Ken-Ryu Han; Jonathan Said; Barbara Gitlitz; Arie S Belldegrun; Robert A Figlin Journal: Cancer Date: 2003-06-15 Impact factor: 6.860
Authors: A Ari Hakimi; Phillip T Koi; Paul M Milhoua; Netta M Blitman; Maomi Li; Vladimir Hugec; Janice P Dutcher; Reza Ghavamian Journal: Urology Date: 2007-11 Impact factor: 2.649
Authors: Pengbo Beck; Barbara Selle; Lukas Madenach; David T W Jones; Christian Vokuhl; Apurva Gopisetty; Arash Nabbi; Ines B Brecht; Martin Ebinger; Jenny Wegert; Norbert Graf; Manfred Gessler; Stefan M Pfister; Natalie Jäger Journal: iScience Date: 2022-03-26